MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Uterine Cervical Neoplasms · Endometrial Neoplasms · Squamous Cell Carcinoma of Head and Neck · Gallbladder Neoplasms · Cholangiocarcinoma · Esophageal Neoplasms · Triple Negative Breast Neoplasms · Hepatocellular Carcinoma · Urinary Bladder Neoplasms · Ovarian Neoplasms · Stomach Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 611 (final count)
- Started
- Sep 16, 2021
- Main results expected
- Aug 5, 2025
- Fully finished
- Aug 5, 2025
- Results posted
- Sep 28, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
Measured over: Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Measured over: Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Measured over: Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
Measured over: 9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
Measured over: 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05007106 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC